Mucalo Iva, Hadžiabdić Maja Ortner, Brajković Andrea, Lukić Sonja, Marić Patricia, Marinović Ivana, Bačić-Vrca Vesna
Centre for Applied Pharmacy, University of Zagreb Faculty of Pharmacy and Biochemistry, A. Kovacica 1, 10000, Zagreb, Croatia.
University of Zagreb Faculty of Pharmacy and Biochemistry, A. Kovacica 1, 10000, Zagreb, Croatia.
Eur J Clin Pharmacol. 2017 Aug;73(8):991-999. doi: 10.1007/s00228-017-2246-y. Epub 2017 Apr 12.
The aim of this study was to measure the prevalence of potentially inappropriate medications (PIMs) by using the EU(7)-PIM list, STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions) version 2 criteria and the new comprehensive protocol.
This prospective study involved a sample of 276 consecutive elderly patients discharged from the university teaching hospital. Age, gender, diagnoses, medication history and medicines at discharge were recorded. The main outcome measure was the prevalence of PIMs according to each set of criteria: EU(7)-PIM list, STOPP version 2 criteria and comprehensive protocol.
The median patient age (range) was 74 (65-92) years. The median number of prescribed medications was 7 (1-17). STOPP identified 393 PIMs affecting 190 patients (69%), EU(7)-PIM list identified 330 PIMs in 184 patients (66.7%) whilst the comprehensive protocol identified 134 PIMs in 102 patients (37%). STOPP version 2 criteria identified significantly more PIMs per patient than the other two protocols (p < 0.001). Gender (p = 0.002), glomerular filtration rate (p = 0.039) and number of comorbidities (p = 0.001) were associated with the proportion of PIMs for the STOPP version 2 criteria only.
A very high PIM prevalence at discharge was reported suggesting the urgent need for actions to reduce them. STOPP version 2 criteria identified significantly more PIMs than the EU(7)-PIM list and the comprehensive protocol and was found as a more sensitive tool for PIM detection.
本研究旨在使用欧盟(7)-PIM清单、STOPP(老年人潜在不适当处方筛查工具)第2版标准和新的综合方案来测量潜在不适当药物(PIM)的流行率。
这项前瞻性研究涉及从大学教学医院连续出院的276名老年患者样本。记录了年龄、性别、诊断、用药史和出院时的药物。主要结局指标是根据每组标准确定的PIM流行率:欧盟(7)-PIM清单、STOPP第2版标准和综合方案。
患者年龄中位数(范围)为74(65-92)岁。处方药物数量中位数为7(1-17)种。STOPP识别出影响190名患者(69%)的393种PIM,欧盟(7)-PIM清单识别出184名患者(66.7%)中的330种PIM,而综合方案识别出102名患者(37%)中的134种PIM。STOPP第2版标准识别出的每位患者的PIM明显多于其他两个方案(p<0.001)。仅对于STOPP第2版标准,性别(p=0.002)、肾小球滤过率(p=0.039)和合并症数量(p=0.001)与PIM比例相关。
据报告出院时PIM流行率非常高,表明迫切需要采取行动减少它们。STOPP第2版标准识别出的PIM明显多于欧盟(7)-PIM清单和综合方案,被发现是一种更敏感的PIM检测工具。